First-line panitumumab combined with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC): data from a phase II, single-arm, multicentre study (20060314)

被引：0
|
作者：
Karthaus, M. [1 ]
Greil, R. [2 ]
Mineur, L. [3 ]
Letocha, H. [4 ]
Thaler, J. [6 ]
Hofheinz, R. [5 ]
Fernebro, E. [7 ]
Gamelin, E. [8 ]
DeCosta, L. [9 ]
Koehne, C.-H. [10 ]
机构：
[1] Klin Hamatol & Onkol, Klinikum Neuperlach, Munich, Germany
[2] Innere Med Klin 3, Salzburg, Austria
[3] Int Sainte Catherine, Avignon, France
[4] Onkol Kliniken, Vasteras, Sweden
[5] Klinikum Mannheim, Mannheim, Germany
[6] Klinikum Wels Grieskirchen, Wels, Austria
[7] Onkol Kliniken, Helsingborg, Sweden
[8] Ctr Paul Papin, Angers, France
[9] Amgen Ltd, Uxbridge, Middx, England
[10] Onkol Klinikum Oldenburg, Oldenburg, Germany
来源：
ONKOLOGIE | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [41] A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma
    Fruehauf, John P.
    Alger, Beverly
    Jakowatz, James G.
    Hsiang, David
    Sender, Leonard S.
    Bettis, Claudette
    Casey, Cameron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping
    Papaxoinis, George
    Kotoula, Vassiliki
    Giannoulatou, Eleni
    Koliou, Georgia-Angeliki
    Karavasilis, Vasilios
    Lakis, Sotirios
    Koureas, Andreas
    Bobos, Mattheos
    Chalaralambous, Elpida
    Daskalaki, Emily
    Chatzopoulos, Kyriakos
    Tsironis, George
    Pazarli, Elisavet
    Chrisafi, Sofia
    Samantas, Epaminontas
    Kaklamanos, Ioannis G.
    Varthalitis, Ioannis
    Konstantara, Athina
    Syrigos, Konstantinos N.
    Pentheroudakis, George
    Pectasides, Dimitrios
    Fountzilas, George
    MEDICAL ONCOLOGY, 2018, 35 (07)
  • [43] Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping
    George Papaxoinis
    Vassiliki Kotoula
    Eleni Giannoulatou
    Georgia-Angeliki Koliou
    Vasilios Karavasilis
    Sotirios Lakis
    Andreas Koureas
    Mattheos Bobos
    Elpida Chalaralambous
    Emily Daskalaki
    Kyriakos Chatzopoulos
    George Tsironis
    Elisavet Pazarli
    Sofia Chrisafi
    Epaminontas Samantas
    Ioannis G. Kaklamanos
    Ioannis Varthalitis
    Athina Konstantara
    Konstantinos N. Syrigos
    George Pentheroudakis
    Dimitrios Pectasides
    George Fountzilas
    Medical Oncology, 2018, 35
  • [44] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [45] Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)
    De Stefano, A.
    Nasti, G.
    Febbraro, A.
    Rosati, G.
    Giuliani, F.
    Santini, D.
    Aprile, G.
    Scartozzi, M.
    Silvestris, F.
    Luppi, G.
    Lolli, I.
    Mastroianni, C.
    Leo, S.
    Montesarchio, V.
    Gridelli, C.
    Pozzo, C.
    Sperti, E.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [47] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [48] Final results from PRECEPT: efficacy and safety of second-line treatment with panitumumab and FOLFIRI in patients with metastatic colorectal cancer (mCRC)
    Cohn, A.
    Smith, D. A.
    Neubauer, M. A.
    Richards, D.
    Watkins, D. L.
    Zhang, K.
    Yassine, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 347 - 347
  • [49] Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.
    Avallone, Antonio
    Giuliani, Francesco
    Nasti, Guglielmo
    Montesarchio, Vincenzo
    Santabarbara, Giuseppe
    Leo, Silvana
    De Stefano, Alfonso
    Rosati, Gerardo
    Lolli, Ivan
    Tamburini, Emiliano
    Colombo, Alfredo
    Santini, Daniele
    Silvestro, Lucrezia
    Facchini, Gaetano
    Mannavola, Francesco
    Febbraro, Antonio
    Troncone, Giancarlo
    Sobrero, Alberto F.
    Giannarelli, Diana
    Budillon, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] SORAFENIB (S) WITH FOLFIRI AS FIRST LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): A PHASE I STUDY
    Maroun, J. A.
    Jonker, D. J.
    Asmis, T.
    Cripps, C.
    Goel, R.
    Yarom, N.
    Vickers, M. M.
    Marginean, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 200 - 200
12345